Interestingly, Crohn's disease and ulcerative colitis are debilitating chronic inflammatory diseases of the digestive tract. The estimated market for biologics in moderate-to-severe IBD patients is estimated to grow to $10 billion.
$IMNP ~
http://www.immunepharma.com/product-portfolio/nanomabs/

$IMNP Website: http://www.immunepharmaceuticals.com/
$IMNP News: http://finance.yahoo.com/q/h?s=IMNP+Headlines
$IMNP Live Chart: http://stockcharts.com/c-sc/sc?s=IMNP&p=d...7425001600